Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
The price of BeOne Medicines Ltd ADR (NASDAQ: ONC) closed at $322.9 in the last session, down -2.56% from day before closing price of $331.4. In other words, the price has decreased by -$2.56 from its previous closing price. On the day, 0.6 million shares were traded. ONC stock price reached its highest trading level at $332.64 during the session, while it also had its lowest trading level at $310.11.
Ratios:
We take a closer look at ONC’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 8.03 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 60.21. For the most recent quarter (mrq), Quick Ratio is recorded 2.17 and its Current Ratio is at 2.39. In the meantime, Its Debt-to-Equity ratio is 0.46 whereas as Long-Term Debt/Eq ratio is at 0.25.
On September 18, 2025, Barclays started tracking the stock assigning a Overweight rating and target price of $385.
On April 07, 2025, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $312.RBC Capital Mkts initiated its Outperform rating on April 07, 2025, with a $312 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Nov 26 ’25 when Sanders Corazon (Corsee) D. sold 2,627 shares for $340.90 per share. The transaction valued at 895,534 led to the insider holds 0 shares of the business.
CORAZON D. SANDERS bought 2,627 shares of ONC for $895,535 on Nov 26 ’25. On Nov 17 ’25, another insider, Wu Xiaobin, who serves as the President and COO of the company, sold 3,991 shares for $380.43 each. As a result, the insider received 1,518,303 and left with 0 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ONC now has a Market Capitalization of 35731447808 and an Enterprise Value of 461491961856. As of this moment, BeOne’s Price-to-Earnings (P/E) ratio for their current fiscal year is 621.20, and their Forward P/E ratio for the next fiscal year is 48.79. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.60 while its Price-to-Book (P/B) ratio in mrq is 8.65. Its current Enterprise Value per Revenue stands at 92.805 whereas that against EBITDA is 1406.255.
Stock Price History:
The Beta on a monthly basis for ONC is 0.46, which has changed by 0.55524516 over the last 52 weeks, in comparison to a change of 0.13506866 over the same period for the S&P500. Over the past 52 weeks, ONC has reached a high of $385.22, while it has fallen to a 52-week low of $170.99. The 50-Day Moving Average of the stock is -2.90%, while the 200-Day Moving Average is calculated to be 12.83%.
Shares Statistics:
According to the various share statistics, ONC traded on average about 274.55K shares per day over the past 3-months and 304040 shares per day over the past 10 days. A total of 101.77M shares are outstanding, with a floating share count of 101.28M. Insiders hold about 0.46% of the company’s shares, while institutions hold 32.24% stake in the company. Shares short for ONC as of 1763078400 were 1330164 with a Short Ratio of 4.84, compared to 1760486400 on 1376140. Therefore, it implies a Short% of Shares Outstanding of 1330164 and a Short% of Float of 1.71.
Earnings Estimates
A comprehensive evaluation of BeOne Medicines Ltd ADR (ONC) is underway, with the input of 10.0 analysts contributing to its current rating.The consensus estimate for the next quarter is $0.51, with high estimates of $1.03 and low estimates of $0.25.
Analysts are recommending an EPS of between $4.29 and $2.45 for the fiscal current year, implying an average EPS of $3.4. EPS for the following year is $6.44, with 16.0 analysts recommending between $9.41 and $1.03.
Revenue Estimates
According to 11 analysts,. The current quarter’s revenue is expected to be $1.46B. It ranges from a high estimate of $1.52B to a low estimate of $1.42B. As of. The current estimate, BeOne Medicines Ltd ADR’s year-ago sales were $1.13BFor the next quarter, 11 analysts are estimating revenue of $1.41B. There is a high estimate of $1.43B for the next quarter, whereas the lowest estimate is $1.36B.
A total of 31 analysts have provided revenue estimates for ONC’s current fiscal year. The highest revenue estimate was $5.44B, while the lowest revenue estimate was $5.12B, resulting in an average revenue estimate of $5.29B. In the same quarter a year ago, actual revenue was $3.81BBased on 33 analysts’ estimates, the company’s revenue will be $6.41B in the next fiscal year. The high estimate is $7B and the low estimate is $5.72B.
